It took a long time, but Volcano (NASDAQ:VOLC) finally found its buyer. Now the question is whether Philips (NYSE:PHG)
can generate the growth and profits from Volcano's platform of
technologies in intravascular imaging and therapeutics that Volcano's
management never could. Investing more resources into image-guided
therapeutics is not a bad call on the surface, but Philips must prove
that it has moved past its legacy of below-average (if not outright
poor) deal integration and must prove that the potential synergies
between these two cath lab companies can win out over competitive
threats from the likes of Boston Scientific (NYSE:BSX) and St. Jude Medical (NYSE:STJ).
Continue reading here:
Philips Looks To Long-Time Laggard Volcano To Perk Up Its Healthcare Biz
No comments:
Post a Comment